GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers-Reference-Cited by-全球学者库

GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers

Published:2020-08 Issue: Volume:485 Page:45-55
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Wang Jun,Xu Wenhao^ORCID,Wang Beihe,Lin Guowen,Wei Yu,Abudurexiti Mierxiati,Zhu Wenkai,Liu Chang,Qin Xiaojian,Dai Bo,Wan Fangning,Zhang Hailiang,Zhu Yao,Ye Dingwei^ORCID

Funder

National Natural Science Foundation of China

Shanghai Key Disciplines Construction Program

Shanghai Rising-Star Program

Fudan University Shanghai Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N. Engl. J. Med.,2009

2. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019;Gillessen;Eur. Urol.,2020

3. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology;Nuhn;Eur. Urol.,2019

4. Managing nonmetastatic castration-resistant prostate cancer;Mateo;Eur. Urol.,2019

5. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study;Beer;Eur. Urol.,2017

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA Let-7a association with glycolysis-induced autophagy in locally advanced gastric cancer: Their role in prognosis and FLOT chemotherapy resistance;Pathology - Research and Practice;2024-01

2. PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?;Journal of Clinical Medicine;2023-11-16

3. Targeting the Metabolic Enzyme PGAM2 Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting BCL2 Signaling;Cancer Research;2023-09-07

4. Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression;Scientific Reports;2023-08-18

5. m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism;Molecular Cancer;2023-08-15